2021-11-15T14:49:45-06:00 2021-06-30 WithumSmithBrown PC ONE TOWER CENTER BLVD 14TH FL EAST BRUNSWICK NJ 08816 990 2020-07-01 843043384 Mission Cure Inc % MEGAN GOLDEN MISS 4013752873 c/o Megan Golden 245 W 107th 15A New York NY 10025 MEGAN GOLDEN PRESIDENT/CEO 4013752873 2021-11-15 true MEGAN GOLDEN XXX-XX-XXXX Brad Caruso P01249134 7328281614 2021-11-02 3 2020 2022-09-23 18:48:47Z X MEGAN GOLDEN c/o Megan Golden 245 W 107th15A New York NY 10025 975250 false X mission-cure.org X 2019 DE THE MISSION OF THE CORPORATION IS TO IMPROVE THE LIVES OF PEOPLE SUFFERING FROM UNSOVLED DISEASES THROUGH PATIENT ENGAGEMENT, INNOVATIVE FINANCING, EDUCATION, AND RESEARCH 4 4 0 10 0 0 950164 0 0 0 55 0 -17500 0 932719 0 0 0 0 0 194037 0 0 8262 0 67564 0 261601 0 671118 0 672489 0 1371 0 671118 X Mission:Cure is a coalition of doctors, researchers, patients, and entrepreneurs pioneering a new approach to curing diseases through innovative outcome-based financing. Mission:Cure collaborates with impact investors and payers to discover life-altering therapies and bring them to patients. false false 229929 1. Developing Therapies: . Defined strategy to cure chronic pancreatitis within 10 years with input from key opinion leaders. . Identified 60 potential drug repurposing candidates that have evidence of action on pancreatitis targets. . Awarded Innovative Practices award for an international data science competition that generated 300 drug repurposing candidates. . Working with biotech Healx's Rare Treatment Accelerator to develop a therapy for chronic pancreatitis. 2.Developed Best-Practices Care Protocol for holistic pancreatitis care, vetted by top experts. . Launched the patient-centered care strategy . Documented and disseminated the lived experience of patients: Designing for Hope and Resilience . Drafted specific care practices to improve patient outcomes and experience . Established Patient-Caregiver Advisory Board . Articulated pancreatitis-specific patient outcomes 3.Engaging Communities . Reached over 77,000 patients, caregivers, clinicians, and scientists . Increased content volume and published content in Spanish, Arabic, and Hebrew . Held patient-focused drug development meeting with FDA & contributed to Voice of the Patient Report . Organized & led patient panel at National Institutes of Health (NIH) meeting to expedite therapies for pancreatitis .Organized & led patient panel at National Institutes of Health (NIH) meeting to expedite therapies for pancreatitis 229929 true true false false false false false false false false false false false false false false false false false false false false false true true false false false false false false false false false false false false false true false false false false false false false false true 3 0 true 0 false false false false false false false false false false false false false X 4 4 false false false false false false false true true false false true true true true true false true true false CA NY X MEGAN GOLDEN 4013752873 245 W 107TH ST 15A New York NY 10025 X Linda Martin Board Chairperson 5.0 0.0 X X 2880 0 0 Megan Golden President and CEO 40.0 0.0 X X 0 0 0 Mickey Levitan Treasurer 5.0 0.0 X X 0 0 0 Bruce Bloom Secretary 5.0 0.0 X X 0 0 0 2880 0 0 0 false false false 0 187150 763014 25031 950164 0 0 0 0 0 0 0 25086 25031 55 55 55 0 187150 17500 -17500 -17500 0 0 0 0 0 0 0 932719 -17445 0 0 0 0 29827 23478 6349 0 143884 140634 3250 0 4260 4052 208 16066 14816 1250 0 0 3099 3099 0 0 0 52010 44691 5243 2076 1232 345 887 1352 625 350 377 8928 933 2233 5762 0 0 0 0 402 355 47 0 0 0 541 541 261601 229929 23410 8262 0 595406 0 0 0 67000 0 0 0 0 0 0 0 0 0 0 0 10083 0 0 0 0 0 0 0 0 0 0 0 0 0 672489 0 1371 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1371 X 0 454118 0 217000 0 671118 0 672489 671118 X true X false true X 0 0 0 0 950164 950164 0 0 0 0 0 0 950164 950164 363022 587142 0 0 0 950164 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X X true Ian Lindsay Live LLC 3216 14TH AVE S SEATTLE WA 98144 LIVE EVENT false 17500 17500 NY Virtual Gala 187150 187150 17500 0 187150 187150 17500 17500 -17500 X 1 25031 FMV false true false Schedule M Part I Line (b) The amount reported on Part I Line B represents the number of contributions. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION PROVIDES A DRAFT COPY OF FORM 990 FOR THE BOARD TO REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C Mission: Cure is committed to avoiding conflicts of interests or the appearance of such conflicts that may call into question the integrity of the organization and its work. There are two primary situations that give rise to conflicts or the appearance of conflicts: when Mission: Cure employees have relationships with parties that do business with Mission: Cure (and in particular, when they give or accept gifts from such parties), and when Mission: Cure employees participate in outside activities that relate to, draw upon or compete with the work of Mission: Cure. In addition, certain contracts have prohibitions on the parties with whom you may do business. Conflict of interest situations are often complex, and you must consult Executive Director before engaging in such activity. FORM 990, PART VI, SECTION B, LINE 13: Mission: Cure will investigate any suspected fraudulent or dishonest use or misuse of Mission: Cure's resources or property by staff, board members, consultants or volunteers. Mission: Cure is committed to maintaining the highest standards of conduct and ethical behavior and promotes a working environment that values respect, fairness and integrity. All staff, board members and volunteers shall act with honesty, integrity and openness in all their dealings as representatives for the organization and comply with all applicable laws and regulations. Failure to follow these standards will result in disciplinary action including possible termination of employment, dismissal from one's board or volunteer duties and possible civil or criminal prosecution if warranted. FORM 990, PART VI, SECTION B, LINE 15: COMPENSATION PROCESS FOR TOP OFFICIAL: THE ORGANIZATION USES THE DEPARTMENT OF LABOR STATISTICS AND SALARY GUIDE TO OBTAIN COMPARABLE DATA ON POSITIONS. FURTHERMORE, THE ORGANIZATION PERIODICALLY REVIEW THE COMPENSATION ARRANGEMENTS AND BENEFITS TO ENSURE THAT THEY ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION AND THE RESULT OF ARM'S LENGTH BARGAINING. FORM 990, PART IV, SECTION C, LINE 19B GOVERNING DOCUMENTS, DISCLOSURE EXPLANATION, THE FINANCIAL STATEMENTS, AND OTHER DOCUMENTS, SUCH AS THE CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION A MEGAN GOLDEN, PRESIDENT AND CEO OF THE ORGANIZATION, DID NOT START RECEIVING COMPENSATION FROM THE ORGANIZATION UNTIL MARCH 2021. FORM 990 PART IX LINE 11G DESCRIPTION:CONSULTING TOTAL FEES:52010